IL17A and asthma: Secukinumab, a fully human anti-IL-17A monoclonal antibody, is now used in rheumatic immune diseases, and a clinical trial has attempted to evaluate its role in patients with asthma not adequately controlled with inhaled corticosteroids but has failed to obtain satisfactory results (NCT01478360).